Patient-oncologist cost communication, financial distress, and medication adherence

Journal of Oncology Practice

Volumn 10, Issue 3, 2014, Pages 162-167

  Bestvina, Christine M ^a,b,c   Zullig, Leah L ^a,b,c   Rushing, Christel ^a,b,c   Chino, Fumiko ^a,b,c   Samsa, Gregory P ^a,b,c   Altomare, Ivy ^a,b,c   Tulsky, James ^a,b,c   Ubel, Peter ^a,b,c   Schrag, Deborah ^a,b,c   Nicolla, Jon ^a,b,c   Abernethy, Amy P ^a,b,c   Peppercorn, Jeffrey ^a,b,c   Zafar, S Yousuf ^a,b,c  

^a DURHAM VA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; COLORECTAL CANCER; CONTROLLED STUDY; DOCTOR PATIENT RELATION; ESOPHAGUS CANCER; FEMALE; FINANCIAL DISTRESS; FINANCIAL MANAGEMENT; FOLLOW UP; HEALTH CARE COST; HEALTH SURVEY; HUMAN; KIDNEY CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; PANCREAS CANCER; PATIENT DECISION MAKING; PRESCRIPTION; PROSTATE CANCER; SARCOMA; TESTIS CANCER; TREATMENT DURATION; UTERUS CANCER; CROSS-SECTIONAL STUDY; ECONOMICS; ETIOLOGY; INTERPERSONAL COMMUNICATION; MENTAL STRESS; NEOPLASMS; PSYCHOLOGY; STATISTICS AND NUMERICAL DATA;

ANTINEOPLASTIC AGENTS; CROSS-SECTIONAL STUDIES; DISCLOSURE; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; NEOPLASMS; PHYSICIAN-PATIENT RELATIONS; STRESS, PSYCHOLOGICAL;

EID: 84907082040     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.2014.001406     Document Type: Article

References (22)

1. Meropol NJ, Schulman KA: Cost of cancer care: Issues and implications. J Clin Oncol 25:180-186, 2007
2. Bernard DS, Farr SL, Fang Z: National estimates of out-of-pocket health care expenditure burdens among nonelderly adults with cancer: 2001 to 2008. J Clin Oncol 29:2821 -2826, 2011
3. Zafar SY, Peppercorn J, Schrag D, et al: The financial toxicity of cancer treatment: A pilot study assessing out-of-pocket expenses and the insured cancer patient's experience. Oncologist 18:381 -390, 2013
4. Cutler DM, Everett W: Thinking outside the pillbox-medication adherence as a priority for health care reform. N Engl J Med 362:1553- 1555, 2010
5. Neugut AI, Subar M, Wilde ET, et al: Association between prescription copayment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. J Clin Oncol 29:2534 -2542, 2011
6. Osterberg L, Blas chke T: Adherence to medication. N Engl J Med 353:487-497, 2005
7. Alexander GC, Casalino LP, Meltzer DO: Patient-physician communication about out-of-pocket costs. JAMA 290:953-958, 2003
8. Schrag D, Hanger M: Medical oncologists' views on communicating with patients about chemotherapy costs: A pilot survey. J Clin Oncol 25:233-237, 2007
9. Meropol N J, Schrag D, Smith TJ, et al: American Society of Clinical Oncology guidance statement: The cost of cancer care. J Clin Oncol 27:3868-3874, 2009
10. Ganz PA, Levit LA: Charting a new course for the delivery of high-quality cancer care. J Clin Oncol 31:4485- 4487, 2013
11. Prawitz AD, Garman ET, Sorhaindo B, et al: Incharge financial distress/financial well-being scale: Dev elopment, administration, and score interpretation. Fin Couns Plan 17:34-50, 2006
12. Ubel PA, Abernethy AP, Zafar SY: Full disclosure- out-of-pocket costs as side effects. N Engl J Med 369:1484- 1486, 2013
13. Zafar SY, Abernethy AP: Financial toxicity, part I: A new name for a growing problem. Oncology (Williston Park) 27:80-81; 149, 2013
14. Mosher CE, Champion VL, Azzoli CG, et al: Economic and social changes among distressed family caregivers of lung cancer patients. Supportive Care Cancer 21:819 -826, 2013
15. . Zullig LL, Peppercorn J, Schrag D, et al: Financial distress, use of costcoping strategies, and adherence to prescription medication among patients with cancer. J Oncol Pract 9:60s-63s, 2013
16. Jacob son JO, Polovich M, McNiff KK, et al: American Society of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards. J Clin Oncol 27:5469-5475, 2009
17. Hershman DL, Shao T, Kushi LH, et al: Early discontinuation and nonadherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treatment 126:529 -537, 2011
18. Dusetzina SB, Winn AN, Abel GA, et al: Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol 32:306 -311, 2013
19. Neugut AI, Subar M, Wilde ET, et al: Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. J Clin Oncol 29:2534 -2542, 2011
20. Briesacher BA, Gurwitz JH, Soumerai SB: Patients at-risk for cost-related medication nonadherence: A review of the literature. J Gen Int Med 22:864-871, 2007
21. Dus etzina SB, Winn AN, Abel GA, et al: Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol 32:306 -311, 2014
22. Gellad WF: Targeted cancer therapy: From bench to bedside to patient. J Clin Oncol 32:268-270, 2014